In recent years, sensitive techniques for assessing biomarkers in plasma have emerged as accessible methods for detecting and potentially predicting early AD changes.6,12 Plasma p-tau markers such as p-tau181, p-tau217, and p-tau231 have shown promising performance at identifying early AD pathology.7,8,12 Among these markers, plasma p-tau217 has shown a superior accuracy in early stages of the disease continuum, serving as a possible first-in-line diagnostic test.13,14. This evidence concerns the gene MAPT and Alzheimer disease.